Contract manufacturing

We offer contract manufacturing capabilities leveraging the quality, reliability and flexibility of our manufacturing facilities. We operate 30 manufacturing plants across the US, Europe and the MENA region.

Leveraging our high-quality local manufacturing expertise.

For all business development enquiries contact:

US and Canada: usbusinessdevelopment@hikma.com

Europe: EUBusinessDevelopment@hikma.com

MENA:
MENABusinessDevelopment@hikma.com

We offer a broad range of capabilities for oral, nasal and injectable products.

 Injectables 

Dosage forms

    Generics 

Dosage forms

Prefilled syringe

Tablets

IV bags

Capsules

Lyophilised

Nasals

Large parenteral

Oral solutions

Small parenteral

 

Specialised products

Specialised products

Cytotoxic/high containment

High containment

Emulsion

Respiratory

Cephalosporins

Controlled substances

Controlled substances

 

Generics

World class contract manufacturing in Columbus, OH, US
You can call us on 614-308-3500

Injectables

Advanced sterile injectable manufacturing operations in the US and Europe

Hikma completes Xellia acquisition

Press Release, Corporate 10 September 2024

Hikma launches Clindamycin in 5% Dextrose Injection in the US

Press Release, Product 03 September 2024
New

Bringing Better Health Within Reach: Improving access to medicine as the partner of choice in MENA

Insight, Corporate 28 August 2024
New

Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fenta...

Press Release, Product 20 August 2024
New

KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months

Press Release, Product 15 August 2024

Hikma delivers strong H1 performance and upgrades Group guidance

Press Release, Financial Results 08 August 2024
New

Hikma Pharmaceuticals: how our three businesses work together to improve health

Insight, Corporate 31 July 2024
New

Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of One Lot of Acetaminophen Injection, 1000mg/100mL, ...

Press Release, Product 22 July 2024
New

Hikma Pharmaceuticals Receives Permanent J-Code for COMBOGESIC® IV (acetaminophen and ibuprofen) injection from Centers ...

Press Release, Product 16 July 2024

Notice of results

Press Release, Corporate 15 July 2024
Related content

Explore more